Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Brief Summary: This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.


Options:
A: Arm Label: Group I (JCAR014, durvalumab) Early - Dose Level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group I (JCAR014, durvalumab) Late- Dose Level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group I (JCAR014, durvalumab) Late - Dose Level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 4; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Arm Label: Group II (durvalumab, JCAR014) - Dose Level 5; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Drug: Cyclophosphamide, Biological: Durvalumab, Drug: Fludarabine | Intervention Type: BIOLOGICAL; Name: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014; Assigned to Arm(s): Group I (JCAR014, durvalumab) Early - Dose Level 2, Group I (JCAR014, durvalumab) Late - Dose Level 2, Group I (JCAR014, durvalumab) Late- Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 2, Group II (durvalumab, JCAR014) - Dose Level 3, Group II (durvalumab, JCAR014) - Dose Level 4, Group II (durvalumab, JCAR014) - Dose Level 5 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Group I (JCAR014, durvalumab) Early - Dose Level 2, Group I (JCAR014, durvalumab) Late - Dose Level 2, Group I (JCAR014, durvalumab) Late- Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 2, Group II (durvalumab, JCAR014) - Dose Level 3, Group II (durvalumab, JCAR014) - Dose Level 4, Group II (durvalumab, JCAR014) - Dose Level 5 | Intervention Type: BIOLOGICAL; Name: Durvalumab; Assigned to Arm(s): Group I (JCAR014, durvalumab) Early - Dose Level 2, Group I (JCAR014, durvalumab) Late - Dose Level 2, Group I (JCAR014, durvalumab) Late- Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 2, Group II (durvalumab, JCAR014) - Dose Level 3, Group II (durvalumab, JCAR014) - Dose Level 4, Group II (durvalumab, JCAR014) - Dose Level 5 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Group I (JCAR014, durvalumab) Early - Dose Level 2, Group I (JCAR014, durvalumab) Late - Dose Level 2, Group I (JCAR014, durvalumab) Late- Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 1, Group II (durvalumab, JCAR014) - Dose Level 2, Group II (durvalumab, JCAR014) - Dose Level 3, Group II (durvalumab, JCAR014) - Dose Level 4, Group II (durvalumab, JCAR014) - Dose Level 5
B: Arm Label: JCAR017 1-dose schedule; Type: EXPERIMENTAL; Interventions: Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule | Arm Label: JCAR017 2-dose schedule (no longer accruing); Type: EXPERIMENTAL; Interventions: Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule | Intervention Type: BIOLOGICAL; Name: JCAR017 (lisocabtagene maraleucel) single-dose schedule; Assigned to Arm(s): JCAR017 1-dose schedule | Intervention Type: BIOLOGICAL; Name: JCAR017 (lisocabtagene maraleucel) 2-dose schedule; Assigned to Arm(s): JCAR017 2-dose schedule (no longer accruing)
C: Intervention Type: PROCEDURE; Name: Procedure - Adoptive cell transfer; Assigned to Arm(s): N/A
D: Arm Label: IM19 CAR-T cells; Type: EXPERIMENTAL; Interventions: Biological: IM19, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: BIOLOGICAL; Name: IM19; Assigned to Arm(s): IM19 CAR-T cells | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): IM19 CAR-T cells | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): IM19 CAR-T cells

Answer: B